PMID- 22235142
OWN - NLM
STAT- MEDLINE
DCOM- 20120306
LR  - 20220310
IS  - 1460-2105 (Electronic)
IS  - 0027-8874 (Linking)
VI  - 104
IP  - 2
DP  - 2012 Jan 18
TI  - Targeted therapies for renal cell carcinoma: review of adverse event management 
      strategies.
PG  - 93-113
LID - 10.1093/jnci/djr511 [doi]
AB  - With the advent of targeted agents for the treatment of renal cell carcinoma 
      (RCC), overall survival has improved, and patients are being treated continuously 
      for increasingly long periods of time. This has raised challenges in the 
      management of adverse events (AEs) associated with the six targeted agents 
      approved in RCC-sorafenib, sunitinib, pazopanib, bevacizumab (in combination with 
      interferon alpha), temsirolimus, and everolimus. Suggestions for monitoring and 
      managing AEs have been published, but there are few consensus recommendations. In 
      addition, there is a risk that patients will be subjected to multiple unnecessary 
      investigations. In this review, we aimed to identify the level of supporting 
      evidence for suggested AE management strategies to provide practical guidance on 
      essential monitoring and management that should be undertaken when using targeted 
      agents. Five databases were systematically searched for relevant English language 
      articles (including American Society of Clinical Oncology abstracts) published 
      between January 2007 and March 2011; European Society of Medical Oncology 
      congress abstracts were hand searched. Strategies for AE management were 
      summarized and categorized according to the level of recommendation. A total of 
      107 articles were identified that describe a large number of different 
      investigations for monitoring AEs and interventions for AE management. We 
      identify and summarize clear recommendations for the management of dermatologic, 
      gastrointestinal, thyroid, cardiovascular, and other AEs, based predominantly on 
      expert opinion. However, because the evidence for the suggested management 
      strategies is largely anecdotal, there is a need for further systematic 
      investigation of management strategies for AEs related to targeted therapies for 
      RCC.
FAU - Eisen, Tim
AU  - Eisen T
AD  - Cambridge University Health Partners, Cambridge, UK. tim.eisen@medschl.cam.ac.uk
FAU - Sternberg, Cora N
AU  - Sternberg CN
FAU - Robert, Caroline
AU  - Robert C
FAU - Mulders, Peter
AU  - Mulders P
FAU - Pyle, Lynda
AU  - Pyle L
FAU - Zbinden, Stephan
AU  - Zbinden S
FAU - Izzedine, Hassan
AU  - Izzedine H
FAU - Escudier, Bernard
AU  - Escudier B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20120110
PL  - United States
TA  - J Natl Cancer Inst
JT  - Journal of the National Cancer Institute
JID - 7503089
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Benzenesulfonates)
RN  - 0 (Indazoles)
RN  - 0 (Indoles)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyridines)
RN  - 0 (Pyrimidines)
RN  - 0 (Pyrroles)
RN  - 0 (Sulfonamides)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 25X51I8RD4 (Niacinamide)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - 624KN6GM2T (temsirolimus)
RN  - 7RN5DR86CK (pazopanib)
RN  - 9HW64Q8G6G (Everolimus)
RN  - 9ZOQ3TZI87 (Sorafenib)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - V99T50803M (Sunitinib)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
EIN - J Natl Cancer Inst. 2012 Apr 18;104(8):638
MH  - Anorexia/chemically induced/therapy
MH  - Antibodies, Monoclonal, Humanized/adverse effects
MH  - Antineoplastic Agents/administration & dosage/*adverse effects/pharmacology
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
MH  - Benzenesulfonates/adverse effects
MH  - Bevacizumab
MH  - Carcinoma, Renal Cell/*drug therapy/*metabolism
MH  - Cardiovascular System/drug effects
MH  - Drug Eruptions/therapy
MH  - Europe
MH  - Everolimus
MH  - Evidence-Based Medicine
MH  - Gastrointestinal Tract/drug effects
MH  - Humans
MH  - Hypothyroidism/chemically induced/therapy
MH  - Indazoles
MH  - Indoles/adverse effects
MH  - Kidney Neoplasms/*drug therapy/*metabolism
MH  - *Molecular Targeted Therapy/methods
MH  - Niacinamide/analogs & derivatives
MH  - Phenylurea Compounds
MH  - Pneumonia/chemically induced/therapy
MH  - Protein Kinase Inhibitors/adverse effects
MH  - Protein-Tyrosine Kinases/antagonists & inhibitors
MH  - Pyridines/adverse effects
MH  - Pyrimidines/adverse effects
MH  - Pyrroles/adverse effects
MH  - Sirolimus/adverse effects/analogs & derivatives
MH  - Sorafenib
MH  - Sulfonamides/adverse effects
MH  - Sunitinib
MH  - TOR Serine-Threonine Kinases/antagonists & inhibitors
MH  - Vascular Endothelial Growth Factor A/antagonists & inhibitors
MH  - Weight Loss/drug effects
MH  - Wound Healing/drug effects
EDAT- 2012/01/12 06:00
MHDA- 2012/03/07 06:00
CRDT- 2012/01/12 06:00
PHST- 2012/01/12 06:00 [entrez]
PHST- 2012/01/12 06:00 [pubmed]
PHST- 2012/03/07 06:00 [medline]
AID - djr511 [pii]
AID - 10.1093/jnci/djr511 [doi]
PST - ppublish
SO  - J Natl Cancer Inst. 2012 Jan 18;104(2):93-113. doi: 10.1093/jnci/djr511. Epub 
      2012 Jan 10.